KRAS and myelodysplastic syndrome: Additionally, mutations that interest the TP53 gene, transcription factors, and signal transduction initiators such as NRAS, KRAS, NF1, JAK2, CBL, and FLT3 are associated with an unfavorable prognostic risk in MDS [10,28].